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Summary: Synovial fluids and sera of patients with inflammatory and metabolic joint diseases contain different
cysteine proteinases. The quantities of cathepsins B and H were determined by newly developed specific
enzyme-linked immunoassay tests (ELISA), with detection limits of 0.5 μ§/1 for cathepsin Β and 3 μ£/1 for
cathepsin H. The values of cathepsin B in normal sera ranged from 0.6 μg/l to 2 μg/l, whereas in sera of
patients with joint diseases they ranged from 1.7 μg/l to 18 μg/l. Cathepsin H was not found in sera (values
below 3 μg/l), but was measurable in patients' synovial fluids. Patients with rheumatoid arthritis have on
average the highest values of cathepsin B in synovial fluids, whereas patients with undifferentiated arthritis
have the highest values of cathepsin H. The results show that cathepsins Β and Η are present in arthritic
synovial fluids, where they may be implicated in destructive processes. There is as yet no clear correlation
between the quantity of each cathepsin released in synovia and the clinical diagnosis or the stage of the
disease.
Introduction
Lysosomal cysteine proteinases, e. g. cathepsins Β and
H, play an important role in the degradation of in-
tracellular tissue proteins (1). It has been suggested
that their extracellular activity contributes to many
pathological processes such as: inflammation, tumour
growth and metastasis, demyelinating diseases, and
cartilage destruction in rheumatoid arthritis or muscle
dystrophy (2). It has been demonstrated, using ra-
dioimmunoassay and enzyme activity assay (3), that
cathepsin Β is secreted from rheumatoid synovial cells
into the synovial fluid, indicating that the secreted
form of cathepsin Β expresses enzyme activity for a
limited period. Once released and active, it may be
involved in the degradation of connective tissue pro-
teins; that cathepsin Β is able to degrade various
connective tissue components in vitro, has been dem-
onstrated for: proteoglycans (4), bovine collagen (5)
and fibronectin (6).
In this paper ELISA tests are described for quantifi-
cation of cathepsins Β and H in control sera and in
sera and synovial fluids of patients with different joint
diseases. Moreover, we have shown that cathepsin B,
determined immunologically in synovial fluid, is com-




Cathepsin B was isolated from human liver as described by
Zvonar (7). Cathepsin H was purified from human kidney
according to Popovic (8).
Samples
Normal sera were obtained from the Blood Transfusion Centre,
Ljubljana, Yugoslavia. Blood samples and synovial fluids of
different joint diseases were supplied by the Rheumatology
Clinic of the University Clinical Centre, Ljubljana, Yugoslavia.
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Twenty one patients were included in the study. The diagnosis
of rheumatoid arthritis was defined according to the American
Rheumatism Association criteria (9). Seronegative spondylar-
thritis, gout, pseudogout and osteoarthritis were diagnosed by
usual laboratory and X-ray criteria. Undifferentiated arthritis
was diagnosed in patients not meeting the above diagnostic
criteria. Their synovial fluid contained more than 0.5 g/1 leu-
kocytes, predominantly polymorphonucleocytes (10). In every
patient, the degree of inflammation was characterized by sedi-
mentation rate. The synovial fluid was aspirated from knee
joints without the use of a local anaesthetic. The samples were
divided into two parts; one was used for determination of the
leukocyte count and differential cell count, the other was im-
mediately centrifuged for 10 min at 10 °C and 500 g in a Sorvall
centrifuge and the supernatant frozen at — 20 °C.
Electrophoresis
SDS-PAGE was performed according to the method of
Laemmli (11), on 40 — 300 g/1 polyacrylamide gels. Pharmacia
kits were used with molecular weight standards (Pharmacia,
Uppsala, Sweden).
Preparat ion of polyclonal ant ibodies
Immunization was carried out according to the procedure de-
scribed by Morton (12). Cathepsins B and H were dissolved in
0.1 ml phosphate-buffered saline, diluted with 0.1 ml FreuncTs
complete adjuvant in a final concentration of 0.6 g/1, and
inoculated into a lymph node of a female New Zealand rabbit.
Two 0.015 mg booster doses were administered intracutaneously
after 30 and 37 days. Blood samples were taken for the deter-
mination of the antibody litres. The animals were bled 10 days
after the last injection, when the titre had reached a dilution of
1:100000. Sera were prepared by centrifugation (1500 g for 15
min at + 4 °C). The sera were kept frozen at —20 °C until use.
Sheep antiserum against cathepsin B was kindly provided by
Dr. P. Scheuber, Munich, FRG. Antibodies against cathepsin
H were purified from rabbit antiserum by Protein A-Sepharose
(Pharmacia, Uppsala, Sweden) as described by Ey (13). Anti-
bodies against human kininogen were purified from rabbit
antiserum, using the same procedure.
Immunoselective anti-cathepsin B antibodies were purified from
rabbit antiserum by use of an immunoadsorbent column con-
taining human liver cathepsin B linked to CNBr-activated Se-
pharose 4B.
Western blot analysis
The specificity of eluted antibodies was tested by Western blot
analysis. In the immunoblotting procedure pure cathepsin B
and H were electrophoretically transferred to nitrocellulose
filters (Schleicher & Schüll BA85, Dassel, FRG) by the proce-
dure of Towbin (14). Immunological detection of antigens was
performed with antibodies against cathepsins B and H in a
concentration of 10 mg/1. After the incubation with peroxidase-
conjugated goat anti-rabbit IgG (Jackson Immuno Research,
Avondale, Pa., USA), the bound conjugate was immunostained
with 1,4-phenylenediamine and catechol (Merck, Darmstadt,
FRG), as described (15).
Double sandwich ELISA test
Microtitre plate wells (Nunc, Denmark) were coated with 0.5
mg/1 of sheep anti-cathepsin B IgG in 15 mmol/1 carbonate
buffer, pH 9.6, overnight at 4 °C. Thereafter the wells were
washed with phosphate-buffered saline (pH 7.1, containing 0.5
g/1 Tween 20), 0.1 ml of the standard solutions or samples (sera
and synovial fluids; diluted with phosphate buffered saline/
Tween containing 20 g/1 bovine serum albumin) were applied
to each well, incubated for 2 h at 37 °C, and washed again after
incubation. Then 0.1 ml of rabbit anti-cathepsin B IgG solution
(2 mg/1 washing buffer containing bovine serum albumin) was
added to each well and incubated again for 2 h at 37 CC. After
washing, the bound rabbit antibodies were determined with
goat antirabbit IgG peroxidase conjugate (dilution 1 :10 000)
for 2 h at 37 CC. After washing with phosphate-buffered saline,
0.1 ml of 0.1 g/1 2,2/-azinobis(3-ethylbenzthiazoline sulphonic
acid) solution and 0.12 g/1 H2O2 solution in 0.01 mol/1 citrate
phosphate buffer, pH 4.5, was added to the wells and the
absorbance measured at 410 nm (Minireaderll Dynatech, Den-
kendorf, FRG) after 30 min of incubation at 37 °C. Blanks,
containing washing buffer instead of samples, were performed
simultaneously.
Alternatively, 3,3', 5,5' tetramethyl benzidine was used as the
substrate for horseradish peroxidase conjugates, prepared as
described (18).
Results
The specificities of the isolated anti-cathepsin B and
H IgGs were proven by immunoblotting. The results
are shown in figure 1. Isolated antibodies for cath-
epsin B reacted only with cathepsin B and showed no
cross-reaction with cathepsin H. Antibodies raised
against cathepsin H were also immunospecific. No
cross-reactivity was observed.
Enzyme-l inked immunosorben t (ELISA) assay con-
di t ions
The sandwich ELISA test for cathepsin B was performed as
described (16). Cathepsin H was determined under the same
conditions as described for the cathepsin B immunoassay. Anti-
cathepsin H IgG concentrations of 5 mg/1 were used for coating;
an optimal dilution of 1:75 of peroxidase-labelled anti-cath-
epsin H IgG (17) was used for detection.
Fig. 1. Western blot analysis of cathepsins B and H.
1) molecular weight standard,
2) cathepsin B,
3) cathepsin H.
After transfer of proteins from SDS-PAGE, the blots
were
a) stained with Amido black,
b) developed with anti-cathepsin B IgG,
c) developed with anti-cathepsin H IgG.
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In order to quantify the amounts of cathepsin B in
normal sera, a more sensitive double sandwich ELISA
test with a detection limit of 0.5 μ§/1 of antigen (fig.
2) was developed. The amount of cathepsin Β found
in normal sera ranged from 0.6 μg/l to 2 g/1 (mean
value 0.96 μg/l with standard deviation of 0.36,
η = 10). Using the same test system the content of
cathepsin B was measured in synovial fluids and sera
(taken simultaneously) of patients with different joint
diseases. Results are shown in table 1.
0.5-
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Fig. 2. Binding curve of cathepsin B in the double sandwich
ELISA for cathepsin B.
Tab. 1. Mean values of cathepsin B in synovial fluids and sera
(taken simultaneously) of patients with different joint





























4 3.8 1.5- 8.2 24.8 27 -39
10 0.96 0.6- 2.0
Tab. 2. Mean values of cathepsin Η determined in synovial
fluids of patients with different joint diseases. Others:
gout (1), pseudogout (1), osteoarthritis (1).






















Cathepsin H was determined in the same samples,
which were used for cathepsin Β determination, using
the sandwich ELISA test (fig. 3). The amount of
enzyme in normal sera was below the detection limit
(below 3 μg/l). The values for cathepsin Η found in






5 10 50 100
Cathepsin Η
500 1000 5000 10000
Fig. 3. Binding curve of cathepsin H in the sandwich ELISA
for cathepsin H.
Possible correlations between the content of cathep-
sins Β (η = 17) and Η (η = 15) and clinical data
(synovial leukocytes, granulocytes and sedimentation
rate) were studied. The values obtained for Pearson's
correlation coefficients (r) were in the range 0.05 —
0.25.
In order to examine whether the cathepsin Β deter-
mined in different body fluids is present in a free or
complexed form, cathepsin B was isolated from syn-
ovial fluid of patients with rheumatoid arthritis, using
an anti-cathepsin B IgG immunoaffmity CNBr-Se-
pharose column. A SDS-PAGE of eluted cathepsin Β
after separation is shown in figure 4a, indicating that




Fig. 4. SDS-PAGE of cathepsin B (3), isolated with anti-cath-
epsin B CNBr-Sepharose column from synovial fluid:
a) under nonreducing and
b) reducing conditions.
1) For comparison: relative molecular mass standards,
2) cathepsin B from human liver.
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cathepsin B in synovial fluid exists only in a com-
plexed form and not as a free enzyme. Under reducing
conditions this complex was dissociated into frag-
ments with molecular weights of 67 000, 74 000 and
96000, as well as 29000 (fig. 4b). Using Western blot
analysis, these proteins were identified as cathepsin B
and kininogen (fig. 5).
Φ
Fig. 5. Immunoblot of cathepsins after SDS-PAGE under re-
ducing conditions.
1) Cathepsin B,
2) Cathepsin Β from synovial fluid.
A: Blots developed with anti-cathepsin B IgG,
B: Blots developed with anti-kininogen IgG.
Discussion
It has been demonstrated that cathepsin B and D are
present extracellularly in rheumatoid synovium. It
was also shown that cathepsin B, when released into
the synovium, retains its initial enzyme activity up to
pH 8.0, as measured using CBz-Phe-Arg-4-methyl-7-
coumarylamide as a fluorescent substrate. The half-
lives of the enzyme at pH 7.5 and 8.0 were found to
be 7 minutes and 1.7 minutes, respectively (3).
In this work the development of enzyme immunoas-
says for cathepsins B and H made it possible to
determine the amount of these two proteinases sepa-
rately and specifically in different biological samples.
Such immunological determination has an advantage
when compared with enzyme activity assays, because
the total amount of enzymes can be measured, re-
gardless of whether they are free or in a complex with
inhibitors (19). It was demonstrated that cathepsin B
in synovial fluid was not detectable in a free form
(fig. 4), but as complexes with proteins with a relative
molecular mass between 67 000 and 96 000. In Western
blot analysis (fig. 5), strong immunoreaction was ob-
served with antikininogen antibodies, proving that
cathepsin B in synovial fluid was complexed with
kininogen, a known inhibitor of cysteine proteinases
(20). Kininogen and other cysteine proteinase inhib-
itors, present in synovial fluid, do not interfere in the
immunological determination of cysteine proteinases
as proved by Kominami (19).
Antibodies raised in rabbits against cathepsins B and
H were specific and did not cross-react (fig. 1), prov-
ing that the antigens used in the present work were
immunologically distinct, similar to cathepsins B and
H from rat liver (21).
The double sandwich ELISA test could detect and
measure 0.5 μg/l of cathepsin B (fig. 2), which is 10
times more sensitive than the previous measurement
(16); in the case of cathepsin H the limit of detection
was 3 μg/l (fig. 3). The high sensitivity of the assay
for cathepsin B also enables the quantification of this
enzyme in samples such as normal sera, which contain
very small amounts (0.96 ± 0.36 g/1).
It is known that serum, plasma or blood in low
dilutions may interfere with certain immunoassays,
such as those for cortisol, progesterone or oestrogen
(22). In our experiments, dilution of sera was not
possible because of the limited amount of cathepsins
in the sample. To prevent unspecific binding, a 20 g/1
bovine serum albumin solution was used. The values
obtained for cathepsin B were in accordance with
results published by Recklies & Mori (23) using RIA.
In our assay, pH 7.1 was used for the antigen-antibody
reaction, which is close to the normal extracellular
pH value; cathepsin B was rapidly enzymatically in-
activated at this pH (24). It is known that the antisera
raised against cathepsin B tend to react only with the
alkali-denaturated enzyme (25). Using assay condi-
tions with alkali denaturation of the lysosomal en-
zyme, the total amount of cathepsin B was deter-
mined.
Different amounts for cathepsins B and H were de-
termined in synovial fluids and sera from various
diseased states (tabs. 1 and 2). The content of cath-
epsin H was in general lower than the content of
cathepsin B. There were only three exceptions, all of
them cases of undifferentiated arthritis. When blood
and synovia were tested simultaneously, the values
for cathepsin B showed a correlation, being clearly
higher in synovial fluid. Patients with rheumatoid
arthritis had on average a higher content of cathepsin
B in their synovial fluids and sera than other patients.
The highest values of cathepsin H were found in
synovial fluids of patients with undifferentiated ar-
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thritis. Within each group of patients we found a wide
range of values for both cathepsins. So far, no cor-
relation has been observed between synovial leuko-
cytes, granulocytes or sedimentation rate, and the
amount of either enzyme. However, different factors
can have an influence on the levels of cathepsins
measured in biological samples, e. g. the clinical treat-
ment, variations between individuals, and other dis-
eases. Also rheumatoid factors have been reported to
disturb certain types of sandwich assay (22).
As cartilage and bone damage in arthritis is thought
to be caused primarily by an imbalance between active
degrading enzymes and their specific inhibitors, which
are secreted from the cells of the inflammed synovium,
the quantification of each enzyme and inhibitor may
be of clinical significance.
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